LAURA HOPE: Open Payments
NPI 1629845706 · HIGHLANDS RANCH, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$468 in 18 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $48 · 2025 $468
Food & beverage: $468
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 3 | $86 |
| Calliditas Therapeutics US Inc. | 3 | $84 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $59 |
| Novartis Pharmaceuticals Corporation | 2 | $53 |
| AstraZeneca Pharmaceuticals LP | 2 | $47 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Merck Sharp & Dohme LLC | 1 | $29 |
| Travere Therapeutics, Inc. | 1 | $28 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
Products named: TARPEYO, Kerendia, Ozempic, Fabhalta, LOKELMA, ACTHAR, PREVYMIS, Rivfloza.
Industry payments across CO — which companies pay providers there.
